P053: The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)

P053: The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)

Bibliographic Details
Main Authors:	Ioanna Xagoraris, Konstantina Stathopoulou, Persa Xyderou, Marzia Palma, Elias Drakos, Theodoros P. Vassilakopoulos, Georgios Z. Rassidakis
Format:	Article
Language:	English
Published:	Wiley 2022-10-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000890780.07220.6f

Similar Items

P052: Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)
by: Ioanna Xagoraris, et al.
Published: (2022-10-01)

P1304: THE NOVEL TUMOR SUPPRESSOR SAMHD1 CONTRIBUTES TO ANTI-TUMOR RESPONSES IN A CGAS-STING-DEPENDENT OR INDEPENDENT PATHWAY IN HODGKIN LYMPHOMA (HL)
by: I. Xagoraris, et al.
Published: (2022-06-01)

P051: Serum procalcitonin levels in newly diagnosed classical Hodgkin Lymphoma (cHL): Correlation with other inflammatory biomarkers
by: Alexia Piperidou, et al.
Published: (2022-10-01)

Sting Is Commonly and Differentially Expressed in T- and Nk-Cell but Not B-Cell Non-Hodgkin Lymphomas
by: Ioanna Xagoraris, et al.
Published: (2022-02-01)

Impact of Tumour Epstein–Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL
by: Mahdi Nohtani, et al.
Published: (2022-09-01)

An overview of cancer/testis antigens expression in classical Hodgkin's lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients
by: Bortoluzzo Adriana B, et al.
Published: (2011-09-01)

The cGAS Paradox: Contrasting Roles for cGAS-STING Pathway in Chromosomal Instability
by: Christy Hong, et al.
Published: (2019-10-01)

cGAS-STING pathway in cancer biotherapy
by: Yang Wang, et al.
Published: (2020-09-01)

P066 (0154) eBEACOPP FOR FRONT-LINE TREATMENT OF PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA (cHL) IN THE REAL WORLD SETTING
Published: (2018-10-01)

The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19
by: Rajabto W, et al.
Published: (2022-06-01)

cGAS-STING triggers inflammaging-associated neurodegeneration
by: José M. Izquierdo
Published: (2023-10-01)

Significance of the cGAS-STING Pathway in Health and Disease
by: Jinglin Zhou, et al.
Published: (2023-08-01)

Role of cGAS–Sting Signaling in Alzheimer’s Disease
by: Manoj Govindarajulu, et al.
Published: (2023-05-01)

Telomere Maintenance and the cGAS-STING Pathway in Cancer
by: Hiroshi Ebata, et al.
Published: (2022-06-01)

The Activation of cGAS-STING in Acute Kidney Injury
by: Sun C, et al.
Published: (2023-10-01)

Intercellular transmission of cGAS-STING signaling in cancer
by: Qirou Wu, et al.
Published: (2023-02-01)

Sensing of viral lung infections by cGAS-STING
by: Lei Fang, et al.
Published: (2022-05-01)

cGAS/STING: novel perspectives of the classic pathway
by: Menghui Gao, et al.
Published: (2020-09-01)

cGAS-STING, an important pathway in cancer immunotherapy
by: Minlin Jiang, et al.
Published: (2020-06-01)

The Complexity of the cGAS-STING Pathway in CNS Pathologies
by: Amelia L. Fryer, et al.
Published: (2021-02-01)

P013: Outcomes of first-line treatment (FL) of classical Hodgkin lymphoma (cHL) in Argentina: a real life multicenter retrospective study
by: Korin Laura, et al.
Published: (2022-10-01)

Chikungunya virus antagonizes cGAS-STING mediated type-I interferon responses by degrading cGAS.
by: L G Webb, et al.
Published: (2020-10-01)

cGAS–STING, an important signaling pathway in diseases and their therapy
by: Qijie Li, et al.
Published: (2024-04-01)

Erratum to Intercellular transmission of cGAS-STING signaling in cancer
by: Qirou Wu, et al.
Published: (2023-04-01)

cGAS-independent STING activation in response to DNA damage
by: Leonie Unterholzner, et al.
Published: (2019-07-01)

cGAS‐STING signaling in cancer: Regulation and therapeutic targeting
by: Xinzou Fan, et al.
Published: (2023-09-01)

Updated roles of cGAS-STING signaling in autoimmune diseases
by: Ya Liu, et al.
Published: (2023-09-01)

cGAS-STING signaling pathway in intestinal homeostasis and diseases
by: Yuchen Yang, et al.
Published: (2023-09-01)

Cancer immunotherapy strategies that target the cGAS-STING pathway
by: Zhuoying Tian, et al.
Published: (2022-10-01)

Function and regulation of cGAS-STING signaling in infectious diseases
by: Yang Du, et al.
Published: (2023-02-01)

Dysregulation of the cGAS-STING Pathway in Monogenic Autoinflammation and Lupus
by: Holly Wobma, et al.
Published: (2022-05-01)

The cGAS-STING Pathway in Hematopoiesis and Its Physiopathological Significance
by: Weinian Liao, et al.
Published: (2020-11-01)

The cGAS-STING Pathway: Novel Perspectives in Liver Diseases
by: Dongwei Xu, et al.
Published: (2021-04-01)

Activation of the cGAS–STING signaling pathway in adenomyosis patients
by: Yun Lin, et al.
Published: (2021-09-01)

Activation of cGAS/STING pathway upon paramyxovirus infection
by: Mathieu Iampietro, et al.
Published: (2021-06-01)

Porcine cGAS-STING signaling induced autophagy inhibits STING downstream IFN and apoptosis
by: Nengwen Xia, et al.
Published: (2022-10-01)

Emerging Roles of cGAS-STING Signaling in Mediating Ocular Inflammation
by: Linbin Zhou, et al.
Published: (2023-10-01)

Crosstalk between cGAS-STING pathway and autophagy in cancer immunity
by: Qijun Lu, et al.
Published: (2023-03-01)

Regulation and function of the cGAS-MITA/STING axis in health and disease
by: Zhi-Dong Zhang, et al.
Published: (2022-02-01)

cGAS-STING pathway as a potential trigger of immunosenescence and inflammaging
by: Carine Raquel Richter Schmitz, et al.
Published: (2023-02-01)